ZIMLAB Zim Laboratories Q2 FY26 results (Jul–Sep 2025) and concall
Zim Laboratories reported a sequential improvement in Q2 FY26, with total operating income rising 23.6% to INR887 million and EBITDA margins expanding to 8.8%. The pharmaceutical segment drove this growth, increasing 30.7% QoQ. However, overall revenue growth was tempered by a decline in the nutraceutical segment due to deferred institutional orders, and the company recorded a net loss of INR4 million, albeit significantly reduced from the previous quarter. The company is actively addressing EU-GMP remediation and expects normalization in H2 FY26.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue down 1.5%, net profit down 90.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 90 | 95 | 109 | 71 | 88 −1% |
| EBITDA | 8 | 12 | 15 | 4 | 6 −26% |
| Net profit | 1 | 4 | 5 | -2 | 0 −90% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
